Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling
- PMID: 41475838
- PMCID: PMC12766798
- DOI: 10.1136/rmdopen-2025-006434
Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling
Abstract
Objective: To investigate the concordance between organ involvement at diagnosis and relapse in granulomatosis with polyangiitis and factors associated with new disease features at relapse.
Methods: Data from a national database of newly diagnosed patients was analysed. Clinical features were recorded at diagnosis and relapse, grouped by organ system. ORs and HRs were used to assess associations between baseline features and first relapse. Factors independently associated with new organ involvement at relapse were identified using multivariable logistic regression.
Results: Among 795 patients (median follow-up 3.5 years), 394 (50%) relapsed; organ involvement at relapse was available for 376 patients. Relapses most often affected ear, nose and throat (ENT), lungs and kidneys. Organ involvement at diagnosis was associated with a higher likelihood of relapse in the same organ: eyes (OR 6.69), lungs (OR 3.35), kidneys (OR 3.58), nervous system (OR 2.90), and mucocutaneous (OR 4.53). Major manifestations associated with a higher likelihood of recurrence were scleritis, pachymeningitis, subglottic stenosis and worsening renal function. For 56% of patients, the first relapse affected only the initially involved organs. Of the 165 patients with new organ manifestations, these were rarely isolated (n=34) and usually occurred alongside involvement of at least one previously affected organ (n=131). In multivariable analysis, systemic, ENT and lung manifestations at diagnosis were associated with a lower risk of new organ disease at relapse.
Conclusion: Although new features can still emerge, organ involvement at diagnosis is associated with a higher likelihood of relapse in the same organ.
Keywords: Epidemiology; Granulomatosis with polyangiitis; Vasculitis.
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: Professor Puéchal has received consulting fees, speaking fees, honouraria and/or funding for congress registration/travel/accommodation from Boehringer Ingelheim, Sanofi, AstraZeneca, GlaxoSmithKline (less than $10 000 each). Professor Iudici has received consulting fees and speaking fees from Boehringer Ingelheim and Vifor Pharma. Professor Terrier has received consulting fees, speaking fees and honouraria from Lilly, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, LFB, Grifols and Vifor (less than $10 000 each). All the authors have been coinvestigators in academic studies for which rituximab was provided by Roche Pharma. No other conflicts of interest are reported. Drs Cohen and Guillevin have no conflicts of interest.
Figures
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous